Delivery Order SPE2DB22D1017-SPE2DB25FG9LT
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,772.81 to AmerisourceBergen Drug Corp for Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with a completion deadline of September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $1,476.51 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with an ultimate completion date of September 10, 2025. This competitive award, issued on September 9, 2025, utilizes firm fixed pricing with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $5,163.02 to AmerisourceBergen Drug Corp for the supply of MICARDIS HCT 40-12.5 mg tablets in unit dose packaging (30 count) on September 2, 2025, with completion expected by September 3, 2025. This contract was awarded on a non-competitive, firm fixed-price basis and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at approximately $1 billion through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Micardis HCT 80-12.5 mg tablets (30-unit dose) valued at $4,139.85. This competitive, firm fixed-price contract was awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, PA, where AmerisourceBergen maintains its corporate headquarters. No set-aside designation was applied to this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,044.82 to supply Micardis HCT 80-25 mg tablet unit dose packages (30 count) with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply...
- This delivery order, awarded on August 28, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30-count) with a ceiling value of $1,742.70 under firm fixed price terms. The contract is non-set-aside and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The...
- The Defense Logistics Agency awarded a $1,108.80 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Micardis HCT 80-12.5 mg tablets in unit dose packaging (30 count). This competitively awarded, firm fixed-price contract has an ultimate completion date of August 29, 2025, with performance conducted at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition in the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Micardis HCT 40-12.5 mg tablet unit dose packages (30 count). This competitive award, valued at $4,145.28 with firm fixed pricing, is scheduled for completion by September 2, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract contains no set-aside designation and represents a routine pharmaceutical procurement supporting...
- This delivery order, awarded on August 27, 2025, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30 count) with a ceiling value of $9,314.20. The contract utilizes firm fixed pricing with an ultimate completion date of August 28, 2025, and was competitively awarded by the Defense Logistics Agency without any set-aside designation. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Micardis HCT 80-12.5 mg tablets in unit dose packaging (30-count) with a ceiling value of $2,508.25. This competitive, non-set-aside award utilizes firm fixed price pricing and carries an ultimate completion date of September 4, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9LTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,631.02 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30 count) on August 11, 2025, with completion due by August 12, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen Drug Corp's larger prime indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor headquartered in Pennsylvania and a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's federal contract portfolio demonstrates extensive experience supplying a broad range of pharmaceutical products, medical supplies, and healthcare commodities across multiple therapeutic domains through competitive award processes. This delivery order for Micardis HCT, a combination antihypertensive medication, exemplifies the company's role in fulfilling routine pharmaceutical supply needs for Defense Health Agency and other federal healthcare customers through the DLA's established procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 8/11/25 |